Navarixin 10 mg

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Chronic Obstructive Pulmonary DiseasePsoriasis

Phase 2

Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)

TerminatedNCT00441701

Merck Sharp & Dohme LLCChronic Obstructive Pulmonary Disease

Start: 2006-12-01End: 2008-10-01Updated: 2019-01-02

A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)

CompletedNCT00684593

Merck Sharp & Dohme LLCPsoriasis

Start: 2007-06-01End: 2007-10-01Updated: 2019-02-05